AE-37 vaccine is under clinical development by NuGenerex Immuno-Oncology and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AE-37 vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AE-37 vaccine overview
AE-37 vaccine (HER-2/neu peptide vaccine, GP2 peptide vaccine) is under development for the treatment of HER-2 positive breast cancer, triple negative breast cancer. The vaccine candidate is administered intradermally. It is a peptide vaccine developed based on li-Key hybrid Technology Platform. It contains human leukocyte antigen (HLA)-A2-restricted immunogenic peptides derived from the HER2/neu protein designed for use in combination with anti-GP2 antibody.
It was also under development for the treatment of prostate, pancreatic and bladder cancer.
NuGenerex Immuno-Oncology overview
NuGenerex Immuno-Oncology, is a drug company. It offers vaccine formulations. The company develops technologies for the treatment of breast and prostate cancer, avian influenza, swine flu, HIV, HPV, diabetes, allergy and acute myelogenous leukemia, among others. It offers pipeline products such as li-key hybrid vaccines and li suppression. NuGenerex Immuno-Oncology uses technology that allows antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. It partners with biotechnology companies and drug development companies for its development programs in cancer, H5 avian influenza and HIV. NuGenerex Immuno-Oncology is headquartered in Wellesley, Massachusetts, the US.
For a complete picture of AE-37 vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
